Tenet Healthcare (NYSE:THC) Reaches New 12-Month High Following Analyst Upgrade

Shares of Tenet Healthcare Corporation (NYSE:THC) hit a new 52-week high during mid-day trading on Wednesday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $265.83 and last traded at $265.58, with a volume of 169186 shares trading hands. The stock had previously closed at $259.45.

THC has been the subject of several other research reports. KeyCorp cut their price target on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Morgan Stanley lifted their price target on shares of Tenet Healthcare from $254.00 to $274.00 and gave the company an “overweight” rating in a report on Monday, July 27th. Royal Bank Of Canada raised their price objective on shares of Tenet Healthcare from $236.00 to $283.00 and gave the company an “outperform” rating in a research report on Monday, July 27th. Stephens reaffirmed an “overweight” rating and issued a $285.00 target price on shares of Tenet Healthcare in a report on Monday, July 27th. Finally, Raymond James Financial set a $270.00 price target on Tenet Healthcare in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $272.25.

Insider Activity

In other Tenet Healthcare news, Director Tammy Romo sold 4,922 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $264.15, for a total transaction of $1,300,146.30. Following the completion of the transaction, the director owned 30,784 shares in the company, valued at $8,131,593.60. This trade represents a 13.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director J Robert Kerrey sold 5,638 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the sale, the director directly owned 16,804 shares in the company, valued at $2,932,634.08. This trade represents a 25.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 41,375 shares of company stock valued at $9,793,347. 0.97% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tenet Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. Triumph Capital Management bought a new position in shares of Tenet Healthcare in the 3rd quarter valued at about $25,000. Activest Wealth Management purchased a new stake in Tenet Healthcare during the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new position in shares of Tenet Healthcare in the 4th quarter worth approximately $29,000. Canada Pension Plan Investment Board bought a new position in shares of Tenet Healthcare during the 2nd quarter valued at approximately $35,000. Finally, Trust Co. of Vermont bought a new stake in Tenet Healthcare in the second quarter worth $37,000. 95.44% of the stock is owned by hedge funds and other institutional investors.

Tenet Healthcare Price Performance

The company has a quick ratio of 1.35, a current ratio of 1.41 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $21.53 billion, a PE ratio of 10.31, a price-to-earnings-growth ratio of 1.02 and a beta of 1.23. The firm’s 50 day simple moving average is $208.09 and its 200 day simple moving average is $203.48.

Tenet Healthcare (NYSE:THC) last released its earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The firm had revenue of $6.04 billion during the quarter, compared to analyst estimates of $5.43 billion. During the same quarter last year, the business earned $4.02 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. As a group, research analysts anticipate that Tenet Healthcare Corporation will post 21.07 EPS for the current fiscal year.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.